Drug Retention Rates and Treatment Discontinuation among Anti-TNF-α Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice
Table 2
Mean duration of anti-TNF-α therapy treatment courses and presence or absence of concomitant DMARDs therapy among patients remaining on therapy and those requiring a therapy change.
Therapy courses discontinued
Therapy courses ongoing
Total
(%)
Mean duration, months (SD)
Concomitant DMARDs, (%)
(%)
Mean duration, months (SD)
Concomitant DMARDs, (%)
(%)
Mean duration, months (SD)
Concomitant DMARDs, (%)
Anti-TNF-α therapy
ADA
28 (28.6)
10.0 (9.0)
4 (44.4)
69 (27.1)
16.5 (15.4)
16 (26.2)
97 (27.5)
14.6 (14.2)
20 (28.6)
ETA
41 (41.8)
22.5 (20.4)
3 (33.3)
139 (54.5)
30.2 (24.7)
24 (39.3)
180 (51.0)
28.5 (23.9)
27 (38.6)
INF
29 (29.6)
16.3 (15.5)
2 (22.2)
47 (18.4)
43.7 (25.6)
21 (34.4)
76 (21.5)
33.3 (25.9)
23 (32.8)
value
0.0149b
0.5414c
<0.0001b
0.0007c
0.0062a
<0.0001b
0.0194c
Disease
AS
14 (14.3)
21.21 (22.2)
1 (11.1)
54 (21.2)
35.9 (24.8)
15 (24.6)
68 (19.3)
32.9 (24.9)
16 (22.9)
PsA
84 (85.7)
16.5 (16.1)
8 (88.9)
201 (78.8)
27.1 (24.0)
46 (75.4)
285 (80.7)
24.0 (22.5)
54 (77.1)
value
0.4037b
0.7752c
0.0976b
0.4544c
0.0073b
0.3945c
Axial involvement
Ax-SpA
25 (25.5)
18.1 (19.5)
5 (55.6)
76 (29.8)
31.5 (23.7)
18 (29.5)
101 (28.6)
28.2 (23.4)
23 (32.8)
PsA
73 (74.5)
16.8 (16.2)
4 (44.4)
179 (70.2)
27.9 (24.7)
43 (70.5)
252 (71.4)
24.7 (23.1)
47 (67.2)
value
0.9023b
0.0300c
0.1937b
0.9538c
0.0467b
0.3801c
Total
98 (27.8)
17.1 (17.0)
9 (9.2)
255 (72.2)
29.0 (24.4)
61 (23.9)
353
25.7 (23.2)
70 (19.8)
SD: standard deviation; ADA: adalimumab; ETA: etanercept; INF: infliximab; AS: ankylosing spondylitis; PsA: psoriatic arthritis; Ax-SpA: axial spondyloarthritis; values were calculated with the use of a stepwise logistic regression adjusted for gender, concomitant DMARDs, and anti-TNF-α therapy. Variables disease and axial involvement were excluded by a stepwise approach (variables being included for and excluded for ). values were calculated by an ANOVA model adjusted for gender, concomitant DMARDs, anti-TNF-α therapy, type of disease, and axial involvement. value from chi-square test.